About Visterra
Visterra is a company based in Cambridge (United States) founded in 2007 by Ram S was acquired by Otsuka in July 2018.. Visterra has raised $116.17 million across 7 funding rounds from investors including Merck, ARE and Serum Institute of India. The company has 79 employees as of December 31, 2020. Visterra offers products and services including Sibeprenlimab, VIS171, and VIS513. Visterra operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Chimerix, argenx and MacroGenics, among others.
- Headquarter Cambridge, United States
- Employees 79 as on 31 Dec, 2020
- Founders Ram S
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Visterra Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Visterra
Visterra offers a comprehensive portfolio of products and services, including Sibeprenlimab, VIS171, and VIS513. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Investigational therapy for IgA nephropathy treatment in clinical trials.
Early-stage development for immune-mediated disease therapies.
Pipeline program targeting hard-to-treat diseases through biologics.
Unlock access to complete
Leadership Team
18 people
Senior Team
17 people
Product Management Team
6 people
Scientist Team
6 people
Associate Team
5 people
Principal Team
4 people
Software Development Team
4 people
Finance and Accounting
3 people
Unlock access to complete
Funding Insights of Visterra
Visterra has successfully raised a total of $116.17M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $46.7 million completed in October 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series C — $46.7M
-
First Round
First Round
(04 Feb 2008)
- Investors Count 16
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2017 | Amount | Series C - Visterra | Valuation | Serum Institute of India , CTI Life Sciences Fund | |
| Sep, 2016 | Amount | Grant - Visterra | Valuation |
investors |
|
| Oct, 2014 | Amount | Series B - Visterra | Valuation | Merck , Vertex Ventures HC |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Visterra
Visterra has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include Merck, ARE and Serum Institute of India. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US focused venture capital firm
|
Founded Year | Domain | Location | |
|
Life sciences-focused venture capital firm
|
Founded Year | Domain | Location | |
|
Stage agnostic VC firm investing primarily in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Visterra
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Visterra
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Visterra Comparisons
Competitors of Visterra
Visterra operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Chimerix, argenx and MacroGenics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company focused on cancer therapeutics development.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Visterra
Frequently Asked Questions about Visterra
When was Visterra founded?
Visterra was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Where is Visterra located?
Visterra is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Visterra a funded company?
Visterra is a funded company, having raised a total of $116.17M across 7 funding rounds to date. The company's 1st funding round was a Series B of $30M, raised on Feb 04, 2008.
How many employees does Visterra have?
As of Dec 31, 2020, the latest employee count at Visterra is 79.
What does Visterra do?
Developer of monoclonal antibodies against infectious diseases. The companys technology is powered by computational tools and techniques, the core of which is Atomic Interaction Network (AIN) analysis, which uniquely identifies an area, or epitope, on the target site that is fundamental to its structure and function. The lead product candidate, VIS410, is a broad-spectrum human monoclonal antibody for the prevention and treatment of both seasonal and pandemic influenza. The companys second product candidate, VIS513, is a human monoclonal antibody for the treatment of dengue that has been shown to broadly neutralize all four dengue virus serotypes.
Who are the top competitors of Visterra?
Visterra's top competitors include Moderna, argenx and Adaptive Biotechnologies.
What products or services does Visterra offer?
Visterra offers Sibeprenlimab, VIS171, and VIS513.
Who are Visterra's investors?
Visterra has 17 investors. Key investors include Merck, ARE, Serum Institute of India, Otsuka, and Gates Foundation.